Combination Chemotherapy in Patients With Newly Diagnosed BPDCN — LpDessai

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Clinical Trial

Official title:
Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Status Active, not recruiting

Clinical Trial Summary

Patients with suspected BPDCN and meeting eligibility criteria will be enrolled in the study. First, BPDCN diagnosis will be confirmed by anatomic pathology (Dr Petrella T, Montreal) and cytologic plus immunophenotyping analysis (Pr Garnache Ottou F, UMR1098 BESANCON). Patients will then receive three 21 days cycles of a combination of chemotherapy (Ida/Metho/L-asp/Dex), followed by an evaluation. Patients with complete response (CR) or complete response with incomplete bone marrow recovery (CRi) will undergo an allo- or auto-SCT and those who are not eligible to the transplantation will have successive 28 days cycles of chemotherapy (Metho/L-asp/Dex). Patients who did not respond to the treatment will be treated by physicians. All patients will be followed for 24 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Neoplasms

Clinical Trial Details

NCT number	NCT03599960
Study type	Interventional
Source	Centre Hospitalier Universitaire de Besancon
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	May 2, 2019
Completion date	November 2024

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05645744` - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Completed	`NCT02113982` - SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia	Phase 1/Phase 2
Recruiting	`NCT04013685` - Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies	Phase 1
Terminated	`NCT03203369` - Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN	Phase 1
Recruiting	`NCT05430971` - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Recruiting	`NCT04230265` - Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies	Phase 1
Terminated	`NCT04109482` - Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.	Phase 1/Phase 2
Recruiting	`NCT06006403` - Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm	Phase 1/Phase 2